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ABSTRACT
INTRODUCTION: The pathogenesis of psoriasis is complex. Genetic factors have a basic role, followed by 
immunological disturbances, which have been found to provoke a chronic inflammatory process affecting 
the skin and joints. The study aimed to establish and analyze the relationship between the inflammatory 
manifestations and vitamin D status in the patients with psoriasis. 
MATERIALS AND METHODS: We examined 113 patients with moderate or severe psoriasis, divided 
into two groups for analysis: presence of psoriasis without psoriatic arthritis (n=73) and with psoriatic 
arthritis (n=40). Clinical data for inflammation were assessed by Psoriasis Area and Severity Index (PASI). 
At hospital admission samples were collected for C-reactive protein (CRP) and blood count, as well as for 
25-hydroxyvitamin D, 25(OH)D. The serum levels of 25(OH)D were tested with immune fluorescent method 
in 92 patients. 
RESULTS: The patients with psoriatic arthritis compared to psoriatic patients without arthritis had higher 
C-reactive protein (31.77 ± 30.61 mg/l vs. 4.13±4.19 mg/l, p<0.0001) and PASI (35.20±11.31 vs. 28.82±12.51, 
р=0.012) but lower 25(OH)D (10.66 ± 8.73 ng/ml vs. 12.98±6.23 ng/ml, p=0.004). A significant correla-
tion was found between the level of CRP and 25(OH)D, r=-0.2631 (p=0.012) and CRP and PASI, r=0.1993 
(p=0.036).
CONCLUSION: The serum level of CRP and 25(OH)D, and the vitamin D deficiency, respectively, could be 
accepted as markers for worse health condition according to the clinical manifestations of psoriasis, as well 
as the comorbid diseases. 
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INTRODUCTION
Psoriasis vulgaris is a common chronic, sys-
temic inflammatory disease with a typical involve-
ment of skin and joints. Current studies discuss the 
complex role of vitamin D in the pathogenesis of pso-
riasis. They suggest the involvement of vitamin D in 
the immune modulation, regulation of keratinocyte 
turnover, and the integrity of the cutaneous barrier 
(1,2). The supporting argument is the identification 
of vitamin D receptors in macrophages, neutrophils, 
dendritic cells and T-lymphocytes (3). Accordingly, 
vitamin D status may be one of the key parameters 
of the functional assessment of the immune system, 
considering cytokine’s and chemokine’s homeosta-
sis (4,5). The serum concentration of 25-hydroxyvi-
tamin D, 25(OH)D, is an important accepted mark-
er in practice, depicting the sum of skin-synthesized 
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diseases as erysipelas, sinusitis, pyoderma, enteroco-
litis, hepatitis, etc. 
The following data were collected: age at di-
agnosis and at admission; gender; body mass index 
(BMI) and waist circumference; C-reactive protein 
(CRP) and erythrocyte sedimentation rate (ESR), 
leukocyte and platelet count, serum level of glu-
cose, lipids, uric acid, and creatinine. Serum levels of 
25(OH)D were calculated in 92 patients by immune 
fluorescent test (ADVIA Centaur Vitamin D Total, 
Siemens) with assay range of 3.7 to 150 ng/ml. Vita-
min D status was classified using 25(OH)D concen-
tration in four conditions: deficiency (25(OH)D <10 
ng/ml), insufficiency (10–30 ng/ml), sufficiency (>30 
ng/ml), and toxicity (>100 ng/ml). Serum 25(OH)D 
levels can be reported in ng/ml (common units) or 
nmol/l (SI units) with conversion formula 1 ng/ml 
=2.5 nmol/l (18,19). 
Тhе disease exacerbation was assessed by the 
Psoriasis Area and Severity Index (PASI). The index 
combines the area of the affected skin (head – 10%; 
upper extremities – 20%; lower extremities 40%; 
trunk – 30% of the whole body surface) and the grade 
of erythema, desquamation and infiltration or indu-
ration (scored for each criteria from 0 to 4). Regard-
ing PASI, the psoriasis was categorized as mild (in-
dex ≤10), moderate (>10, ≤30), and severe (30 to 72), 
respectively (20). 
Psoriatic arthritis was established by the pres-
ence of 3 or more criteria, according to accepted 
CASPAR (Classification Criteria for Psoriatic Arthri-
tis) by National Psoriatic Foundation (21). The in-
cluded 113 patients were divided into two groups for 
analysis: presence of psoriasis without psoriatic ar-
thritis (group 1, n=73) and psoriatic arthritis (group 
2, n=40).
The continuous variables were expressed as 
mean value with standard deviation. The differenc-
es between variables were analyzed with the Mann-
Whitney test and Kruskal-Wallis test (in an analy-
sis of more than 2 independent variables). The rela-
tionships between 25(OH)D, CRP and other markers 
with disease characteristics were assessed using the 
Spearman correlation coefficients. The Fisher’s exact 
test was used to analyze the contingency tables with 
categorical values. The statistics was performed with 
GraphPad Prism software, a trial 5.0 version. 
and food-derived (alimentary) vitamin D (6). In the 
light of current epidemiological studies, a serum lev-
el of 25(OH)D above 30 ng/ml (75 nmol/l) is neces-
sary for prevention of the bone pathology and for the 
optimal action of the other organs and systems (7).
C-reactive protein (CRP) is an established 
marker of inflammation. It is produced by the liver 
and is known as an acute-phase reagent (8). The level 
of CRP is used to assess the inflammatory processes 
in the patients with psoriasis as well as the comorbid 
diseases with common pathogenic mechanisms (9-
11). Both the skin and joint involvement in psoriasis 
share the same inflammatory pathogenesis (12,13). 
Elevation of CRP was found predominantly in mod-
erate and severe psoriasis but not in mild forms of the 
disease (14).  
Interestingly, the psoriatic patients with vita-
min D insufficiency have higher CRP, sedimentation 
rate and risk of osteoporosis (15). The presence of ar-
thritis in men with psoriasis is significantly associat-
ed with hypovitaminosis D (16). A recent trial evalu-
ating the serum vitamin D level in 120 patients with 
arthritis established insufficiency and deficiency of 
vitamin D in 74% and 13% of the cases with psoriatic 
arthritis, 94% and 39% of the cases with rheumatoid 
arthritis and 97% and 38% of the cases with osteoar-
thritis, respectively. According to these findings the 
authors recommend vitamin D supplementation in 
all patients with arthritis (17).
Our study aimed to analyze the relationship be-
tween the vitamin D status of patients with psoriasis 
and clinical and laboratory markers for inflammato-
ry manifestations of the disease.
MATERIALS AND METHODS
The study included 113 adult patients with clin-
ical manifestations and histological confirmation of 
psoriasis vulgaris evaluated in the Clinic of Derma-
tology and Venereology at the St.Marina University 
Hospital for a 3-year period. The patients had mod-
erate and severe forms of the disease (PASI >10). The 
cases treated with systemic therapy with biological 
agents or on a standard treatment with Acitretine, 
Cyclosporin, Methotrexate, PUVA or photothera-
py were excluded from analysis. Other exclusion cri-
teria were vitamin D supplementation, presence of 
neoplasm or concomitant acute or chronic infectious 
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RESULTS
The included 113 cases were 66 male and 47 fe-
male patients, with a mean age of 55.14 years (range 
of 19 to 81 years). 35% of the cohort of 113 patients 
had psoriatic arthritis. The mean age of the group 
2 patients of 56.85±11.98 years was not different to 
the age of all studied patients as well as the patients 
in group 1. The distribution of type of psoriasis is 
also equal in both patient’s groups: type 1 psoriasis 
was observed in 57.53% and type 2 – in 42.47% of 
patients with psoriatic arthritis. The severity of dis-
ease, assessed by PASI was not different in psoriat-
ic patients with type 1, compared to type 2 of psori-
asis. We found 47.83% prevalence of 25(OH)D defi-
ciency and a very high rate of insufficiency - 96.74%. 
It was interesting to find, that 25(OH)D was low-
er in group 2 patients – mean 10.66 ng/ml, median 
7.91 ng/ml (95% CI 7.61–13.71 ng/ml), compared to 
group 1 – mean 12.98 ng/ml, median 12.16 ng/ml 
(95% CI 11.34–14.62 ng/ml), p=0.004, Figure 1. Also, 
the patients with psoriatic arthritis have a signifi-
cantly higher level of serum CRP (31.77±30.61 mg/l), 
compared to the group 1 patients without arthritis 
(4.13±4.19 mg/l), p<0001, as shown in Figure 2. In 
addition, the patients with psoriatic arthritis suffered 
from a more severe psoriatic disease than the patients 
in group 1: PASI 35.20±11.31 vs. 28.82±12.51, respec-
tively (р=0.012), Figure 3.
A mild but significant correlation between CRP 
level and PASI was observed (Spearman r=0.1993, 
p=0.036). The serum CRP concentration was in-
versely related to the calculated 25(OH)D (r=-0.2631), 
p=0.012. The proportion of patients with 25(OH)D 
deficiency with elevated CRP was increased com-
pared to the psoriatic patients with 25(OH)D level 
above 10 ng/ml: 67.4% vs. 46.8%. However, the dif-
ference was not significant (p=0.057). 
DISCUSSION
The reported incidence of psoriatic arthritis is 
3.4 to 8 per 100 000 in the whole population and the 
frequency of joint involvement in psoriatic patients 
has varied from 6 to 42% (22,23). In our cohort we 
found it to be 35%. The variations are probably due 
to difficulties in the diagnosis of psoriatic arthritis, 
the need for a clinical experience of dermatologists 
and a cooperation with rheumatologists but also for 
available laboratory and image diagnostic tests. The 
acceptance of common diagnostic criteria – CAS-
PAR certainly contributes to the accuracy of epide-
miological and clinical trials (21,24). In a study of 
Figure 1. Serum level of 25-hydroxyvitamin D in the pa-
tients with psoriasis with and without psoriatic arthritis
Figure 2. Level of serum C-reactive protein in the patients 
with psoriasis with and without psoriatic arthritis
Figure 3. Severity of psoriasis, assessed by PASI in the pa-
tients with psoriasis with and without psoriatic arthritis
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174 psoriatic patients with comorbidities Gospodi-
nov et al. observed a 53% frequency of psoriatic ar-
thritis. Accordingly, psoriatic arthritis was assessed 
as the second most common comorbidity in patients 
with psoriasis, after arterial hypertension, found in 
96 of 174 patients (55.17%) (25). The high prevalence 
of psoriatic arthritis of 35% in our study may be ex-
plained by the characteristics of psoriatic patients, 
having PASI>10 and it was previously stated that se-
vere forms of psoriasis with large plaques and nail 
involvement in psoriasis have been associated with 
psoriatic arthritis (26).
The role of the measurement of serum CRP for 
assessment of severity and progression of disease was 
broadly studied in psoriatic cohorts of patients (14). 
In general, psoriatic patients had higher CRP, com-
pared to the control groups; CRP concentrations 
were in association with the severity of psoriasis and 
a systemic therapy may achieve a decrease and nor-
malization of the CRP (27). This relationship was ob-
served in the subgroups of psoriatic patients with 
moderate and severe disease but not consistently in 
the patients with mild psoriasis. Therefore, in psoria-
sis without arthritis the CRP measurement may have 
an additive role or even replace PASI for assessment 
of disease exacerbation (14). 
In our study, the group 2 psoriasis with arthri-
tis patients had a CRP of 31.77±30.61 mg/l that was 
significantly increased compared to group 1 patients 
without arthritis. The elevation of CRP in psoriat-
ic patients with comorbidities, incorporated to met-
abolic syndrome was previously established (28). 
Thus, the CRP level is a recommended part of the in-
vestigations in psoriasis as an appropriate marker for 
cardiovascular risk and psoriasis severity.  
The growing number of studies evaluated the 
connection of vitamin D and immune inflamma-
tion. Recent study established lower vitamin D in 43 
patients with plaque psoriasis, compared to 55 pa-
tients with rheumatoid arthritis, but an association 
with the CRP levels and PASI was not found (29). In 
contrast, a negative correlation between vitamin D 
and the CRP, PASI and Ischemia-modified albumin 
(as a marker for oxidative stress) was discovered in 
43 patients with psoriasis (30). According to our data 
based on 92 psoriatic patients, an association of lev-
els of CRP and overall decreased 25(OH)D could be 
established. 
CONCLUSIONS
The clinical course of inflammation in patients 
with moderate and severe psoriasis and psoriasis 
with psoriatic arthritis could be assessed by simple, 
known markers as CRP and PASI. The serum level 
of 25(OH)D and vitamin D deficiency, respectively, 
may be accepted as a marker for a deteriorated health 
condition according to the clinical manifestations 
of psoriasis, as well as the comorbid diseases. Fur-
ther prospective studies designed to estimate the as-
sociation between vitamin D, psoriasis, biochemical 
markers of metabolic syndrome and immunological 
abnormalities are needed.
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